Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (Beijing Institute of Biological Products)
- Development stage
- Preclinical
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The DTaP-IPV combination vaccine is an investigational multi-antigen vaccine being developed by the Beijing Institute of Biological Products (BJBPI). It is designed to provide simultaneous protection against four major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. The vaccine formulation typically consists of diphtheria and tetanus toxoids, acellular pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus (IPV) types 1, 2, and 3. As an adsorbed vaccine, it likely utilizes an aluminum-based adjuvant to enhance the immune response. By combining these antigens into a single injection, the vaccine aims to simplify pediatric immunization schedules, reduce the number of required injections, and improve vaccination compliance. It is currently in the preclinical development stage.
- Other names
- DTaP-IPV combination vaccineAdsorbed DTaP-IPV Combination Vaccine吸附无细胞百白破-脊髓灰质炎联合疫苗DTaP-IPV vaccineDiphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine
02
Targets
PT (Pertussis toxin)Poliovirus type 1 capsid proteinTT (Tetanus toxoid)FHA (Filamentous hemagglutinin)Inactivated poliovirus type 2 antigenPRN (Pertactin)
Beyond the preview
Go deeper on diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (Beijing Institute of Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (Beijing Institute of Biological Products).